The Filing Desk

BeyondSpring

BYSI · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

BYSI · Last close · November 19, 2026
$0.44
Value BeyondSpring yourself

BeyondSpring reported revenue of $0 million in fiscal 2025. Free cash flow was −$20 million.

BeyondSpring Inc. Latest fiscal year ended December 31, 2025 10-K filed March 25, 2026 · 0001171843-26-001908 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$1M
 
Free cash flow
−$20M
 
Return on equity
—
 
Market cap
$18M
Nov 19 close
P/E
—
 

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What BeyondSpring does

BeyondSpring is a drug developer in the clinical stage: it has no approved medicines and earns no revenue from product sales. Its main drug candidate is Plinabulin, a small-molecule cancer drug derived from a compound found in marine microorganisms. The company says Plinabulin works by helping immune cells called dendritic cells mature, which may help patients whose cancer has stopped responding to immunotherapy, and that it can also reduce a drop in white blood cells caused by chemotherapy.

Its most advanced work is in non-small cell lung cancer, the most common type of lung cancer. A completed late-stage trial, DUBLIN-3, enrolled 559 patients and tested Plinabulin with the chemotherapy drug docetaxel against docetaxel alone. BeyondSpring plans to seek approval in China and to run a new global trial. Hospitals in China and the US are also testing Plinabulin with other cancer drugs. It has three more drug candidates at an early, pre-clinical stage, and says it plans to look for a partner to sell Plinabulin outside China if it is approved.

BeyondSpring founded SEED Therapeutics, which works on a way of breaking down disease-causing proteins and has partnerships with Eli Lilly and Eisai. BeyondSpring owns about 38.03% of SEED and has agreed to sell part of that stake. The company is incorporated in the Cayman Islands, has its main office in New Jersey and offices in China, and had 44 full-time employees in early 2026, including 34 at SEED.

Its biggest risks, as it describes them

  • Its reliance on Plinabulin: if trials fail or approval is delayed or refused, the business would be badly harmed.
  • It has lost money every year since it began and needs more funding, which could dilute shareholders.
  • Regulators in the US, China or Europe may decide its trial results are not strong enough and ask for more trials.
  • It has no sales and marketing team of its own and plans to rely on partners to sell any approved drug.
  • Its reliance on outside firms to run its clinical trials and studies.
From BeyondSpring's annual report on Form 10-K, filed March 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

BeyondSpring lost money in fiscal 2025: a net loss of $1 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments7237—313
Debt incl. finance leases20000
Net debt (negative means net cash)−71−37—−3−13
Net debt to EBITDA—————
Debt to equity0.1x————
Interest coverage−761.4x−2,190.5x———
Current ratio5.0x5.2x2.3x2.6x1.5x
Quick ratio5.0x5.2x2.3x2.6x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project BeyondSpring's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of BeyondSpring reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''−54.17−37.37−52.32
Accruals ratio−12.8%18.0%62.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't rise———
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put BeyondSpring side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BeyondSpringFY25——————
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000011000
Revenue growth—————650.6%0.0%−100.0%——
Gross profit——————————
Research and development10895231423726734
Operating income−12−98−58−40−64−66−37−15−9−9
Net income−12−92−55−38−61−64−33−21−11−1
Diluted EPS (US$)−0.75−4.40−2.42−1.55−2.03−1.64————
Diluted shares (millions)16212325303939———
Cash flow
Cash from operations−14−29−40−48−44−47−28−16−16−20
Capital expenditure0000030000
Free cash flow−14−29−40−48−44−50−28−17−17−20
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation—2372832121
Balance sheet at fiscal year end
Cash and short-term investments12314361107237—313
Debt incl. finance leases———1220000
Total assets15337451178246253426
Total liabilities351613255549484950
Shareholders' equity1227−8308827−6−27−33−32
Margins and ratios
Gross margin——————————
Operating margin————−35,672.8%−4,903.0%−2,756.4%———
Net margin————−33,873.9%−4,750.5%−2,463.3%———
Free cash flow margin————−24,331.7%−3,707.3%−2,035.4%———
Rule of 40 (growth + FCF margin)—————−3,056.8%−2,035.4%———
Return on capital——————————
Return on equity−113.8%−467.8%−568.3%−338.4%−102.8%−111.6%−321.5%———
Return on assets−92.8%−384.5%−275.1%−147.6%−75.5%−64.6%−52.0%−59.2%−37.6%−3.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: BeyondSpring's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with BeyondSpring.